UY26424A1 - Método para tratar la diabetes - Google Patents

Método para tratar la diabetes

Info

Publication number
UY26424A1
UY26424A1 UY26424A UY26424A UY26424A1 UY 26424 A1 UY26424 A1 UY 26424A1 UY 26424 A UY26424 A UY 26424A UY 26424 A UY26424 A UY 26424A UY 26424 A1 UY26424 A1 UY 26424A1
Authority
UY
Uruguay
Prior art keywords
treating diabetes
post
prandial
diabetes
glyburide
Prior art date
Application number
UY26424A
Other languages
English (en)
Spanish (es)
Inventor
Beth Anne Piper
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26424A1 publication Critical patent/UY26424A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY26424A 1999-11-03 2000-11-02 Método para tratar la diabetes UY26424A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes

Publications (1)

Publication Number Publication Date
UY26424A1 true UY26424A1 (es) 2001-05-31

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26424A UY26424A1 (es) 1999-11-03 2000-11-02 Método para tratar la diabetes

Country Status (23)

Country Link
EP (1) EP1229918B1 (https=)
JP (1) JP5183844B2 (https=)
KR (1) KR20070089259A (https=)
CN (1) CN1450902A (https=)
AR (1) AR026356A1 (https=)
AT (1) ATE390140T1 (https=)
AU (1) AU780106B2 (https=)
BR (1) BR0015294A (https=)
CA (1) CA2389928C (https=)
EE (1) EE05260B1 (https=)
HU (1) HU229352B1 (https=)
IL (1) IL149139A0 (https=)
LT (1) LT5058B (https=)
LV (1) LV12910B (https=)
MX (1) MXPA02004282A (https=)
NO (1) NO330026B1 (https=)
NZ (1) NZ518278A (https=)
PL (1) PL199278B1 (https=)
RU (1) RU2275915C2 (https=)
SK (1) SK287810B6 (https=)
TW (1) TWI280125B (https=)
UY (1) UY26424A1 (https=)
WO (1) WO2001032157A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
EP1680115A1 (en) * 2003-10-30 2006-07-19 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
SG149814A1 (en) * 2003-12-19 2009-02-27 Omega Bio Pharma Ip3 Ltd Compositions and methods for treating diabetes
MXPA06012752A (es) * 2004-05-03 2007-02-14 Omega Bio Pharma Ip3 Ltd Cisteaminas para tratar complicaciones de hipercolesterolemia y diabetes.
EA020870B1 (ru) 2007-07-19 2015-02-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
RS56990B1 (sr) 2007-09-10 2018-05-31 Janssen Pharmaceutica Nv Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
RU2372911C1 (ru) * 2008-03-12 2009-11-20 Николай Евгеньевич Староверов Полиморфная аналоговая терапия
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
SG10201506114UA (en) 2010-05-11 2015-09-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
AU2012213435B2 (en) * 2011-02-02 2017-03-30 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
KR20060105005A (ko) 1997-06-18 2006-10-09 스미스클라인비이참피이엘시이 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
AU738804B2 (en) * 1997-12-08 2001-09-27 Bristol-Myers Squibb Company Novel salts of metformin and method
ES2206868T3 (es) * 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
WO2001032157A2 (en) 2001-05-10
EP1229918B1 (en) 2008-03-26
SK287810B6 (sk) 2011-10-04
PL364885A1 (en) 2004-12-27
NO20022087D0 (no) 2002-05-02
JP5183844B2 (ja) 2013-04-17
SK5002002A3 (en) 2004-05-04
CA2389928A1 (en) 2001-05-10
HU229352B1 (en) 2013-11-28
NZ518278A (en) 2004-10-29
AU1082601A (en) 2001-05-14
HUP0300218A3 (en) 2006-02-28
HUP0300218A2 (hu) 2003-06-28
EP1229918A2 (en) 2002-08-14
EE05260B1 (et) 2010-02-15
CN1450902A (zh) 2003-10-22
LT2002063A (en) 2003-06-25
WO2001032157A3 (en) 2002-01-24
AU780106B2 (en) 2005-03-03
CA2389928C (en) 2010-03-23
TWI280125B (en) 2007-05-01
PL199278B1 (pl) 2008-09-30
JP2003519621A (ja) 2003-06-24
IL149139A0 (en) 2002-11-10
ATE390140T1 (de) 2008-04-15
NO20022087L (no) 2002-06-24
KR20070089259A (ko) 2007-08-30
BR0015294A (pt) 2003-07-15
LT5058B (lt) 2003-09-25
EE200200242A (et) 2003-12-15
MXPA02004282A (es) 2003-02-17
RU2002114820A (ru) 2004-03-10
AR026356A1 (es) 2003-02-05
LV12910B (en) 2003-05-20
RU2275915C2 (ru) 2006-05-10
NO330026B1 (no) 2011-02-07

Similar Documents

Publication Publication Date Title
UY26424A1 (es) Método para tratar la diabetes
HK1045655A1 (zh) 由二甲雙胍及伏降糖組合構成的藥劑成份
Groop et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans
FI3524261T3 (fi) Exendin käytettäväksi diabeteksen hoidossa ja ruumiin painon vähentämiseksi
AR047779A1 (es) Composiciones y metodos para tratar diabetes
ATE372782T1 (de) Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes
WO2000016797A3 (en) Use of glp-1 or analogs in treatment of stroke
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
MXPA05006634A (es) Fluidos de dialisis biocompatibles que contienen icodextrinas.
PT88029A (pt) Processo para a preparacao de derivados piperazinilo de purinas e seus isoesteres uteis como agentes hipoglicemicos
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
TR200103409T2 (tr) Glukoz çıkışı arttırıcıları olarak naftalen üreleri.
ES2183952T3 (es) Tratamiento de diabetes tipo ii con dosis elevadas de tripicolinato cromico.
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
Negrişanu et al. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy
CN205073517U (zh) 一种加速康复型心血管护理装置
Duhault et al. The pharmacology of S 1702, a new highly effective oral antidiabetic drug with unusual properties. 2. Protective activity of S 1702 on the microvascular system in normal and diabetic rats
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
RU2004103531A (ru) Фармацевтическая композиция для перорального применения, содержащая одновременно метформин и гликлазид
JP2022541322A5 (https=)
RU2002109173A (ru) Способ лечения дистрофических заболеваний сетчатой оболочки глаза
Aman et al. Clinical trial with glipizide in uncomplicated maturity onset diabetes mellitus
MX2021014997A (es) Agente de vanadio y metformina como principio activo para el tratamiento de padecimientos relacionados con la resistencia a la insulina.
Greco Oral hypoglycemic agents for noninsulin-dependent diabetes mellitus in the cat
Foy et al. Oral antihyperglycemic therapy for type 2 diabetes: Clinical applications

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20121123